Tetraphase Pharmaceuticals Announces Presentation of Data

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Tetraphase Pharmaceuticals Announces Presentation of Data at ASM Microbe 2016

WATERTOWN, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH ) today announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place June 16-20 in Boston, MA.  Presentations will include information about the company’s lead drug candidate, eravacycline, as well as data from its TP-271 program.  

The details for the data presentations at ASM Microbe 2016 are as follows:

Eravacycline presentations: Poster #264:  Intravenous Eravacycline With Transition To Oral Therapy for Treatment of Complicated Urinary Tract Infections (cUTI) Including Pyelonephritis:  Results From A Randomized, Double-Blind, Multicenter, Phase 3 Trial (IGNITE2) Date and time:  Monday, June 20 from 12:30 – 2:30 p.m. ET Session info:  Laboratory Diagnosis and Antimicrobial Susceptibility of UTI Pathogens

Poster #265:  Intravenous Eravacycline Compared to Intravenous Levofloxacin for the Treatment of Complicated Urinary Tract Infections (cUTI):  Subgroup Analysis from a Randomized, Double-Blind, Phase 3 Trial (IGNITE2) Date and time:  Monday, June 20 from 12:30 – 2:30 p.m. ET Session info:  Laboratory Diagnosis and Antimicrobial Susceptibility of UTI Pathogens

Poster #266:  Risk Factors for Change in Microbiological Outcomes between the End of Therapy (EOT) and Post-Treatment (PT) Evaluations in Patients with Complicated UTI (cUTI) Treated with Eravacycline (ERV):  Analysis from a Randomized, Double-Blind, Phase 3 Trial (IGNITE2) Date and time:  Monday, June 20 from 12:30 – 2:30 p.m. ET Session info:  Laboratory Diagnosis and Antimicrobial Susceptibility of UTI Pathogens

Poster #426:  Evaluation of Patients with Complicated Intra-abdominal Infections (cIAI) and Concomitant Bacteremia (CB) from IGNITE1: A Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline (ERV) versus Ertapenem (ETP) in Complicated Intra-Abdominal Infections (cIAI) Date and time:  Friday, June 17 from 12:30 – 2:30 p.m. ET Session info:  Evaluation of Clinical Outcomes among Patients with Gram-negative Bloodstream and Complicated Infections

Poster #451:  Patient Outcomes with Complicated Intra-Abdominal Infections (cIAI) Caused by Gram-Negative Pathogens from IGNITE1: A Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline (ERV) versus Ertapenem (ETP) Date and time: Saturday, June 18 from 12:45 – 2:45 p.m. ET Session info:  Evaluation of Clinical Outcomes among Patients with Gram-negative Bloodstream and Complicated Infections

Poster #005:   In Vitro Activity of Eravacycline and Comparators Against Enterobacteriaceae , Including Strains Resistant to Carbapenems or 3rd/4th Generation Cephalosporins in the US  Date and time:   Monday, June 20 from 12:30 – 2:30 p.m. ET  Session info:  Antimicrobial Susceptibility Testing of Newer and ReNewed Antimicrobial Agents

Poster #007 :   In Vitro Activity of Eravacycline and Comparators Against Acinetobacter baumannii , Including Carbapenem-resistant Strains, and Stenotrophomonas maltophilia Isolated from Patients in the US Date and time:  Monday, June 20 from 12:30 – 2:30 p.m. ET Session info:  Antimicrobial Susceptibility Testing of Newer and ReNewed Antimicrobial Agents

Poster #008:  Eravacycline In Vitro Activity Against Clinical Isolates Obtained from Genitourinary (GU) and Gastrointestinal (GI) Sources from Patients in the US Date and time:  Monday, June 20 from 12:30 – 2:30 p.m. ET Session info:   Antimicrobial Susceptibility Testing of Newer and ReNewed Antimicrobial Agents

Poster #566:  Eravacycline is Active against MDR, Cephalosporin- and Carbapenem- Resistant Enterobacteriaceae and Acinetobacter baumannii Date and time:  Monday, June 20 from 12:30 – 2:30 p.m. ET Session info:  Tetracyclines, Aminoglycosides, and Related Compounds

Poster #550:  Eravacycline In Vitro Antibacterial Activity against 110 Carbapenemase-Producing Enterobacteriaceae Clinical Isolates Date and time:  Monday, June 20 from 12:30 – 2:30 p.m. ET Session info:  Tetracyclines, Aminoglycosides, and Related Compounds

Poster #568:  Activity of Eravacycline and Comparators against 6,338 Pathogens Isolated from Canadian Hospitals: Canward 2014 and 2015 Date and time:   Monday, June 20 from 12:30 – 2:30 p.m. ET Session info:  Tetracyclines, Aminoglycosides, and Related Compounds

Poster #511:  Antibacterial Efficacy of Eravacycline (ERV) In Vivo Against Gram-positive and Gram-negative Organisms Date and time:   Monday, June 20 from 12:30 – 2:30 p.m. ET Session info:  Pharmacokinetic/Pharmacodynamic (PK/PD) of New Drugs

Oral presentation title: Eravacycline (ERV) Pharmacokinetics (PK) and Challenges in Defining Humanized Exposure In Vivo Date, time and location:   Sunday, June 19 at 8:45 a.m. ET, Meeting Room 156A Session info:  Innovations and Challenges in Pharmacokinetics/Pharmacodynamics (PK/PD)

TP-271 presentation: Poster #536:  TP-271 is Efficacious in a Francisella tularensis Cynomolgus Monkey Treatment Model Date and time:  Monday, June 20 from 12:30 – 2:30 p.m. ET Session info:  Tetracyclines, Aminoglycosides, and Related Compounds

Additional presentations: Oral presentation title:  The Impact of ramR Sequence Variations on Tigecycline Susceptibility in Klebsiella pneumoniae Date, time and location:  Monday, June 20 at 8:15 a.m. ET, Meeting Room 157A Session info:  RNA Modulation and Cellular Signals in Antimicrobial Resistance

Poster #140:  Multidrug Resistance Gram-negative (MDR-GN) Organisms in the Inpatient and Outpatient Settings in the US: 2008-2015 Date and time:  Monday, June 20 from 12:30 – 2:30 p.m. ET Session info:  Drugs, Bugs, Body Sites and Antibiograms

Poster #145:  Multidrug-resistance Acinetobacter baumannii (MDR AB) Trends from All Sources in the Inpatient and Outpatient Setting in US Hospitals: 2008-2015 Date and time:  Monday, June 20 from 12:30 – 2:30 p.m. ET Session info: Drugs, Bugs, Body Sites and Antibiograms

ASM Microbe 2016 is the integration of two of the American Society of Microbiology’s meetings: the General Meeting and ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy). Full abstracts can be found on the ASM Microbe website at http://www.asmmicrobe.org/ .

About Tetraphase Pharmaceuticals, Inc. Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes its late-stage antibiotic, eravacycline, as well as two additional antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.

 

Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 tdahlman@tphase.com Argot Partners Susan Kim 212-600-1902 susan@argotpartners.com Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 Mikebeyer@sambrown.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shanghai Import Expo Draws 4,000 Global Companies Again

Updated Category News Views 132

Shanghai spent last week making a rather pointed commercial argument: China wants to be seen buying, not merely selling. The ninth China International Import Expo, or CIIE, brought together more than 4,000 overseas companies and participants from 162 countries, regions and international organizations. That is a serious gathering by any reasonable measure, even if the...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 85

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
Getac's Linux Certification Matters at the Rugged Edge

Updated Category News Views 73

Field computers rarely get applause, but they can decide whether a critical operation runs cleanly or turns into a very expensive mess. Getac’s November 19 announcement that its UX10, G140, and V120 rugged devices are certified for Red Hat Enterprise Linux is not the sort of headline that sends investors pounding the table. It is, however, the kind of plumbing work that...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 28

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 0

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 169

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 59

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 87

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 66

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 121

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading

Top 5 Most Recently Viewed Articles

EQT AB Faces Challenges Following UBS's Rating Cut

Updated Category News Views 124

EQT AB Stock Drops After UBS Downgrade Recently, shares of EQT AB (ST:EQTAB) took a hit as UBS decided to downgrade the stock from "neutral" to "sell." This change in outlook comes amid rising worries over valuation risks and anticipated earnings in the short term. Market Response and Current Trading Situation Following the downgrade, EQT AB saw its trading price dip by...

Continue Reading
AMTD's 'The Last Dance' Sets Record in Hong Kong Film Scene

Updated Category News Views 221

AMTD's Groundbreaking Film Success AMTD Group Inc., alongside its subsidiaries AMTD IDEA Group (NYSE: AMTD; SGX: HKB) and AMTD Digital Inc. (NYSE: HKD), has achieved a remarkable milestone in the film industry with its new release, 'The Last Dance.' This film has not only shattered nine major records in Hong Kong's cinematic landscape but has also surpassed the impressive...

Continue Reading
Community Healthcare Trust Boosts Q4 Dividend Reflecting Growth

Updated Category News Views 441

Community Healthcare Trust Increases Dividend for Fourth Quarter Community Healthcare Trust Incorporated (NYSE: CHCT) has recently made an exciting announcement regarding its upcoming dividend. This decision reflects the company's ongoing commitment to delivering value to its shareholders and demonstrates its robust financial health. Many investors eagerly await the news...

Continue Reading
NielsenIQ and OpenBrand Partner to Enhance Market Insights

Updated Category News Views 1043

NielsenIQ and OpenBrand Forge a Revolutionary Alliance NielsenIQ (NIQ) stands at the forefront of consumer intelligence, and their recent partnership with OpenBrand is set to redefine the landscape of market intelligence in the consumer electronics sector. This collaboration harnesses both companies' strengths to offer advanced solutions designed for retailers,...

Continue Reading
Florida Quantum Initiative Sparks Revolutionary Tech Development

Updated Category News Views 327

Florida Quantum Initiative Launched to Boost Technology Innovation MIAMI — Just recently, leaders from Florida's technology sector proclaimed the launch of Florida Quantum, a groundbreaking initiative designed to accelerate and organize the state's quantum economy. This exciting announcement came during the eMerge Americas' Tech Basel AI Summit Miami, showcasing...

Continue Reading